Joint Pain Injections

Global Joint Pain Injections Market to Reach US$5.5 Billion by 2030

The global market for Joint Pain Injections estimated at US$3.8 Billion in the year 2024, is expected to reach US$5.5 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Hyaluronic acid injections, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Corticosteroid injections segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 10.4% CAGR

The Joint Pain Injections market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 10.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Joint Pain Injections Market – Key Trends & Drivers Summarized

The joint pain injections market is witnessing significant growth due to the rising prevalence of arthritis, osteoarthritis, and other musculoskeletal disorders. With an aging global population and increasing lifestyle-related joint issues, demand for effective, minimally invasive pain management solutions has surged. Joint pain injections, including corticosteroids, hyaluronic acid, platelet-rich plasma (PRP), and stem cell-based therapies, are widely used to alleviate pain, improve mobility, and delay surgical interventions such as joint replacement. Advances in biologics, precision medicine, and regenerative therapies are further transforming the market, making joint pain management more effective and personalized.

What Are the Emerging Trends Shaping the Joint Pain Injections Market?

One of the most notable trends in the joint pain injections market is the growing preference for regenerative medicine, particularly platelet-rich plasma (PRP) and stem cell-based injections. PRP therapy, derived from the patient’s own blood, is increasingly being used to promote tissue healing and reduce inflammation in osteoarthritis and sports injuries. Similarly, stem cell injections, particularly mesenchymal stem cells (MSCs), are being researched for their ability to regenerate cartilage and delay disease progression. As patients seek alternatives to corticosteroids and hyaluronic acid, the adoption of regenerative therapies is expected to grow, supported by ongoing clinical trials and research advancements.

Another significant trend is the rise of personalized medicine in joint pain management. Advances in genetic testing, biomarker analysis, and imaging technologies are enabling physicians to tailor injection treatments to individual patient profiles. Personalized treatment plans improve efficacy, reduce side effects, and optimize outcomes by identifying the most suitable injection type based on the severity of joint degeneration, inflammatory response, and overall patient health. This shift towards precision medicine is enhancing patient satisfaction and driving demand for advanced diagnostic tools alongside joint pain injections.

Minimally invasive techniques and image-guided injection procedures are also gaining traction. The use of ultrasound and fluoroscopy for precise needle placement has improved the accuracy and effectiveness of joint injections, reducing pain and minimizing complications. Image-guided injections are particularly beneficial for deep-seated joints such as the hip and spine, where traditional blind injections may be less effective. As technology advances, more clinics and hospitals are adopting guided injection procedures, leading to improved patient outcomes and higher market demand.

How Are Technological Advancements Driving the Market?

Technological innovations are revolutionizing the joint pain injections market by enhancing the effectiveness, safety, and longevity of treatments. One of the most significant advancements is the development of next-generation viscosupplementation therapies. Traditional hyaluronic acid injections provide temporary relief by lubricating the joint, but newer formulations with cross-linked hyaluronic acid offer longer-lasting effects and improved viscoelastic properties. These advancements have made viscosupplementation more appealing to patients with mild to moderate osteoarthritis who want to delay joint replacement surgery.

Another breakthrough is the development of long-acting corticosteroid injections with controlled-release technology. Traditional corticosteroid injections provide rapid pain relief but have a short duration of effect. Newer formulations with microsphere-based delivery systems are being designed to provide sustained anti-inflammatory benefits over several months. These innovations are particularly beneficial for patients with chronic joint pain who require prolonged relief without frequent injections.

Biologics and cell-based therapies are also making significant strides in joint pain management. Exosome therapy, a novel regenerative approach, is gaining attention for its potential to repair cartilage damage and modulate inflammation at a cellular level. Unlike PRP and stem cells, exosome-based injections are acellular, meaning they contain only the beneficial signaling molecules derived from stem cells, reducing the risk of immune rejection or adverse reactions. As research in regenerative medicine advances, exosome therapy and other novel biologics are expected to become key players in the joint pain injections market.

What Is Driving the Growth of the Joint Pain Injections Market?

The growth in the joint pain injections market is driven by several factors, including the increasing prevalence of osteoarthritis and chronic joint disorders, the rising demand for non-surgical pain management solutions, and advancements in biologics and regenerative medicine. The aging global population is a major contributor to market expansion, as older individuals are more susceptible to joint degeneration and arthritis. According to the World Health Organization (WHO), osteoarthritis is among the leading causes of disability worldwide, fueling the need for effective, long-lasting joint pain treatments.

The expanding role of sports medicine and orthopedic rehabilitation is also a significant market driver. Athletes and physically active individuals frequently experience joint injuries that require minimally invasive treatments for faster recovery. PRP injections and other biologic therapies are increasingly being used in sports medicine to accelerate healing and reduce downtime, contributing to the growing demand for joint pain injections. Additionally, the increasing number of outpatient and ambulatory care centers offering injection-based pain management solutions is improving patient access and market penetration.

Another critical growth driver is the growing acceptance of combination therapies for joint pain. Physicians are increasingly combining different injection types—such as PRP with hyaluronic acid or corticosteroids with stem cell therapy—to enhance treatment outcomes. This multi-modal approach not only provides immediate pain relief but also supports long-term joint health by addressing both inflammation and tissue regeneration. As combination therapies gain traction, market players are investing in clinical research to develop optimized treatment protocols that maximize efficacy and patient satisfaction.

As the demand for effective, minimally invasive joint pain solutions continues to rise, the market for joint pain injections is expected to grow significantly. Advances in regenerative medicine, biologic therapies, and personalized treatment approaches will play a key role in shaping the future of the industry, offering patients better alternatives to surgery and long-term pain relief.

SCOPE OF STUDY:

The report analyzes the Joint Pain Injections market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Injection Type (Hyaluronic acid injections, Corticosteroid injections, Platelet rich plasma injections); Joint Type (Knee, Shoulder & elbow, Ankle & hip, Other joint types); End-Use (Hospitals, Clinics, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• AbbVie Inc.
• Anika Therapeutics, Inc.
• Arthrex, Inc.
• Bioventus LLC
• Chugai Pharmaceutical Co., Ltd.
• Dr. Reddy`s Laboratories Ltd.
• Eli Lilly and Company
• Emcyte Corporation
• Ferring Pharmaceuticals
• Flexion Therapeutics, Inc.
• Lifecore Biomedical
• Ono Pharmaceutical Co., Ltd.
• OrthogenRx, Inc.
• Pacira BioSciences, Inc.
• Pfizer Inc.
• Sanofi
• SEIKAGAKU CORPORATION
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd.
• Zimmer Biomet Holdings, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.